Helixmith Co., Ltd (KOSDAQ:084990)
6,590.00
-230.00 (-3.37%)
Dec 10, 2025, 3:30 PM KST
Helixmith Revenue
Helixmith had revenue of 564.70M KRW in the quarter ending September 30, 2025, a decrease of -68.68%. This brings the company's revenue in the last twelve months to 3.74B, down -3.58% year-over-year. In the year 2024, Helixmith had annual revenue of 4.97B with 18.38% growth.
Revenue (ttm)
3.74B
Revenue Growth
-3.58%
P/S Ratio
83.95
Revenue / Employee
98.44M
Employees
38
Market Cap
314.04B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 4.97B | 772.35M | 18.38% |
| Dec 31, 2023 | 4.20B | 1.40B | 50.08% |
| Dec 31, 2022 | 2.80B | 483.36M | 20.87% |
| Dec 31, 2021 | 2.32B | -1.93B | -45.48% |
| Dec 31, 2020 | 4.25B | -206.22M | -4.63% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2013 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2012 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 5.50T |
| Celltrion | 3.90T |
| Yuhan | 2.14T |
| Hanmi Pharm. | 1.47T |
| SK Biopharmaceuticals | 675.41B |
| Sam Chun Dang Pharm. | 220.74B |
| ALTEOGEN | 202.18B |
| LigaChem Biosciences | 159.27B |
Helixmith News
- 19 days ago - A Look Into Vipshop Holdings Inc's Price Over Earnings - Benzinga
- 8 months ago - P/E Ratio Insights for Vipshop Holdings - Benzinga
- 1 year ago - Price Over Earnings Overview: Vipshop Holdings - Benzinga